Our Science
Our Science
Partnerships
Arvinas’ PROTAC Degraders Power Our Partnerships
Our PROTAC Discovery Engine has driven some of the industry’s most significant targeted protein degradation breakthroughs and led to our robust preclinical and clinical pipeline, as well as the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader therapy.
To expand the universe of druggable targets, we are working both on our own and with strategic partners, including leading drug companies, academic experts, and others, to broaden and further accelerate our clinical programs.
In addition to our disclosed partnerships, Arvinas has multiple undisclosed pipeline and platform collaborations to improve upon its protein degrader engine.
Learn About Our Current Partnerships and Licenses
We are expanding the potential impact of PROTACs for patients with our current partners and/or licensees: Pfizer, Novartis, Rigel Pharmaceuticals, and Genentech.
In January 2018, Arvinas announced a research and collaboration license agreement with Pfizer Inc. for the discovery and development of drug candidates using Arvinas’ PROTAC Discovery Engine, which is designed to degrade key disease-causing proteins.
In July 2021, Arvinas and Pfizer Inc. announced a global collaboration to develop and commercialize vepdegestrant, at that time an investigational, oral, PROTAC estrogen receptor degrader. In May 2026, following the FDA approval of VEPPANU™ (vepdegestrant), Arvinas and Pfizer Inc. entered into a license agreement with Rigel Pharmaceuticals, Inc. for the exclusive global development, manufacturing, and commercialization rights for VEPPANU. Arvinas and Pfizer will receive $85 million in upfront and transition payments and are eligible to receive up to $320 million in development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales.
In May 2024, Arvinas out-licensed luxdegalutamide (ARV-766), also known as JSB462, its second generation PROTAC androgen receptor degrader for patients with prostate cancer, and sold its preclinical AR-V7 program, to Novartis AG. Arvinas received a one-time, upfront payment in the aggregate amount of $150 million and is eligible to receive up to an additional $1.01 billion as contingent payments based on specified development, regulatory, and commercial milestones for luxdegalutamide being met, as well as tiered royalties based upon worldwide net sales of luxdegalutamide.
In November 2017, Arvinas and Genentech, a member of the Roche Group, expanded their multi-year strategic license agreement to encompass additional disease targets. The collaboration was originally formed in October 2015 to develop new therapeutics using Arvinas’ PROTAC Discovery Engine.
One target remains under the Genentech agreement.
Opportunities for New Partnerships
We are open to partnerships with commercial and academic partners that extend our PROTAC Discovery Engine, including:
- Targets of potential interest to Arvinas
- Addressing new or different disease areas
- Leveraging novel E3 ligases for incorporation into PROTACs
- Targets or E3 ligases with ligands with suboptimal affinity or without function
- Targets with nontraditional binding ligands
- Novel approaches to identifying chemical binders
- Platform collaborations
- Partnerships on Arvinas’ pipeline programs
Interested in Partnering with Arvinas?
VEPPANU™ is a trademark of Arvinas Operations, Inc.